Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialSteven E. Lipshultz, Steven D. Colan, Yvan Samson et al.|The Lancet Oncology|2010Cited by 452
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac OutcomesSteven E. Lipshultz, Stephen E. Sallan, Tracie L. Miller et al.|PEDIATRICS|2012Cited by 176
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemiaSteven E. Lipshultz, Lewis B. Silverman, Stuart R. Lipsitz et al.|Cancer|2013Cited by 160
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL ConsortiumLynda M. Vrooman, Stephen E. Sallan, Donna Neuberg et al.|European Journal of Cancer|2011Cited by 117
Health Status and Health-related Quality of Life Measurement in Pediatric Cancer Clinical Trials: An Examination of the DFCI 00-01 Acute Lymphoblastic Leukemia ProtocolCharlene Rae, Ronald D. Barr, William Furlong et al.|Journal of Pediatric Hematology/Oncology|2018Cited by 7